Parkinson's Disease
Conditions
Keywords
Parkinson's Disease, stereotactic transplantation
Brief summary
The purpose of this study is to evaluate the safety and efficacy of stereotactic transplantation of hAESCs for Parkinson's disease.
Detailed description
The study plans to recruit 3 participants with Parkinson's disease . Using stereotactic technology, hAESCs will be accurately transplanted into the lateral ventricle. Therapeutic effectiveness and safety of hAESCs on PD will be evaluated. hAESCs are derived from placental amnion donated after cesarean section in healthy women. hAESCs is developed from the epiblast as early as 8 days after fertilization, recent reports indicate that hAESCs have some characteristics of neural stem cell. These cells are able to differentiate into dopaminergic neurons and secrete dopamine and various neurotrophic factors. These HAESCs could be seen as one of the best potential stem cell source for treating Parkinson's disease.
Interventions
BIOLOGICALHuman Amniotic Epithelial Stem Cells
Stereotactic transplantation of hAESCs for participants with PD.
Sponsors
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Shanghai East Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study plans to recruit 3 patients who meet the criteria. 50 millions HAESCs will be transplanted to participants with PD.
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. 30-70 years old, with primary Parkinson's disease more than 5 years, male or female; 2. The off-stageHohen and Yahr grade of Parkinson's disease is from 2 to 4; and theoff-stageUPDRS score is 38-70, difference between two scores before treatment is less than 10% ; 3. The dosage of medicine is stable for more than 3 months; 4. Levodopa treatment was effective ; 5. Stable condition, good control of complications, no general anesthesia contraindications, no contraindications to stereotactic surgery and other conditions that interfere with clinical evaluation; 6. No abnormalities affecting cell transplantation were found through head MRI; 7. Patients shall be properly cared during treatment, and caregivers can provide assistance to the researcher if necessary.
Exclusion criteria
1. Atypical Parkinson's disease, such as Parkinson's syndrome, secondary Parkinson's disease; 2. Only having tremor syndrome; 3. Serious movement disorders and cannot complete any routine exercise tasks; 4. Symptoms of severe neurological deficits caused by other diseases; 5. Severe mental symptoms or dementia; 6. Patients are unwilling to cooperate or incapable of completing self-evaluation, and cannot complete the evaluator with the help of a doctor; 7. History of striatum or extrapyramidal surgery, including deep brain stimulation (DBS); 8. Ongoing treatment of apomorphine injecting ; 9. Coagulation disorders or ongoing anticoagulation therapy; 10. Women of childbearing age who do not take effective contraception; 11. Pregnant or lactation; 12. Patients who have participated in other clinical studies of drugs or medical devices within 3 months; 13. Botox toxin, phenol, subarachnoid injection of baclofen or interventional therapy for the treatment of dystonia or spasticity within 6 months; 14. History of seizures or taking prophylactic anti-epileptic drugs; 15. General anesthesia or stereotactic surgery contraindications, such as sleep apnea, chronic obstructive pulmonary disease; 16. Other circumstances judged by the investigator that may cause negative effect to the subject; 17. Alcohol or drug abuse; 18. Used diazepam within 3 months; 19. Severe cognitive impairment, depression, or behavioral disorder, defined as the Mini-Mental State Assessment Scale (MMSE) of less than 26 points, and the Hamilton Depression Rating Scale (HAMD) of greater than 35 points; 20. Chest CT shows active disease or tumor; 21. Currently suffering from or ever had a tumor other than cutaneous basal cell tumor and cervical carcinoma in situ; 22. The detection of HIV, hepatitis B virus(HBV), hepatitis C virus (HCV), syphilis and other infection indicators before surgery can not exclude HIV and syphilis infection; 23. Abnormal liver and kidney normal function tests in the laboratory, liver and kidney function is defined as Alanine aminotransferase（ALT）, Aspartate aminotransferase（AST） is less than 2.5 times the upper limit of normal, blood urea nitrogen (BUN) and Creatinine（Cr） are less than the upper limit of normal. 24. Other situations not suitable for enrollment judged by investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with adverse event and serious adverse event | 12 months | An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an adverse event that meets at least one of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other significant medical hazard. Whether an adverse event was treatment-related (TRAE) or not was determined by investigator. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the Hoehn and Yahr scale | day 0, 1 month, 2 month, 3 month, 6 month, 9 month and 12 month. | Hoehn and Yahr scale is used to provide a general estimate of clinical function of PD patients, combining functional deficits (disability) and objective signs (impairment). The Hoehn and Yahr score ranges from 0 to 5, with higher score indicating higher dysfunction of PD patients. |
| Changes in Parkinson's Disease Questionnaire (PDQ-39) | day 0, 1 month, 2 month, 3 month, 6 month, 9 month and 12 month. | PDQ-39 provides the evidence of the quality of life of a PD patient. The higher the score, the lower the quality of life of PD patients. |
| Changes in the Schwab and England score | day 0, 1 month, 2 month, 3 month, 6 month, 9 month and 12 month. | The Schwab and England scale develop a scale that describes the capacity of daily living shown by a PD patient. It measures the following three areas: dependence, abilities, and awareness. The Schwab and England scores range from 0% to 100%, with higher scores indicating greater healthy status. |
| Changes in Unified Parkinson's Disease Rating Scale (UPDRS) in ON and OFF state | day 0, 1 month, 2 month, 3 month, 6 month, 9 month and 12 month. | UPDRS is used for evaluating the impairment and disability associated with Parkinson's Disease (PD). It consists of four sections: (1) Mentation, behavior, and mood; (2) Activities of daily living (ADLs); (3) Motor; and (4) Complications. The UPDRS score ranges from 0 to 199, with higher score indicating greater disability. |
| Cranial doparmin transporter measured by positron emission tomography(PET)-magnetic resonance Imaging(MRI) | 4 month, 6 month | Changes of cranial expression of dopamine transporter investigated by PET-MR |
| Glucose metabolism measured by 18F-Fluoro-2-deoxy-glucose (FDG) PET scan | 4 month, 6 month | Changes in cranial glucose metabolism investigated by PET-MR |
| Differences in biochemical indicators of cerebrospinal fluid | day 0, 1 month, 2 month, 3 month, 4 month,5 month,6 month, 9 month and 12 month. | Cerebrospinal fluid indicator tests include biochemical indicators and the following parameters: Dopamine (DA), high vanillic acid (HVA), 5-hydroxytryptamine (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), norepinephrine (MHPG), α synuclein (α-synuclein), amyloid deposition (Aβ42), Tau protein (Tau) Protein, Neurofilament light (NF-L), and yKL-40 (YKL-40). |
| Levodopa equivalent daily dose | day 0, 1 month, 2 month, 3 month, 4 month, 5 month, 6 month, 9 month and 12 month. | Differences in daily dosage of levodopamine |
Countries
China
Outcome results
None listed